Media ReleasesImmutep

View All Immutep News

Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital

• Extends the Company’s cash runway into mid-2020, during which time Immutep is expected to report meaningful clinical data

SYDNEY, AUSTRALIA – December 19, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces it has entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors to purchase 260,000,000 ordinary shares represented by 2,600,000 American Depositary Shares (“ADSs”) at a purchase price per ADS of US$2.00 in a registered direct offering, for total gross proceeds of approximately US$5.2 million (equivalent to A$7.2 million). In a concurrent private placement, the Company has agreed to issue warrants to purchase up to 208,000,000 ordinary shares represented by 2,080,000 ADSs. The warrants will have an exercise price of US$2.50 per ADS and will be exercisable immediately following the close of this private placement and will expire three years from the date of effectiveness of the registration statement registering for resale the ordinary shares underlying the warrants. The registered direct offering is being led by Altium Capital, a U.S.-based healthcare investment fund founded by CEO, Jacob Gottlieb, with participation from another investor.

For further information please download PDF attached:
Download this document